TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30044295

Group type: EXPERIMENTAL
Intervention: Nasal tip lifting group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lower pathway
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Upper pathway
Number of subjects: 86
Study: 28167721

Group type: EXPERIMENTAL
Intervention: Personalized letters and e-mails with information about potential savings on insurance premiums
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic communications emphasizing the possibility of saving
Number of subjects: 0
Study: 26376765

Group type: EXPERIMENTAL
Intervention: Topical administration of mupirocin (three times a day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Topical administration of mupirocin (once a day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Single povidone iodine (PVP-I)
Number of subjects: 4
Study: 24354929

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily) plus Ezetimibe (10 mg daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 22733462

Group type: EXPERIMENTAL
Intervention: Catheter-based renal sympathetic denervation (RD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 20302811

Group type: EXPERIMENTAL
Intervention: Surgical management (tonsillectomy/adeno-tonsillectomy)
Number of subjects: 729

Group type: COMPARATOR
Intervention: Medical management (non-surgical conventional treatment)
Number of subjects: 729
Study: 18400276

Group type: EXPERIMENTAL
Intervention: Bardscan
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bladderscan
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3D‐US system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Voided volume
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All methods (Bardscan, Bladderscan, 3D‐US)
Number of subjects: 50
Study: 15735443

Group type: EXPERIMENTAL
Intervention: Indinavir + stavudine + lamivudine (group 1)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Indinavir + stavudine + nevirapine (group 2)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Antiretroviral-naive patients
Number of subjects: 141

Group type: COMPARATOR
Intervention: Pretreated patients
Number of subjects: 141
Study: 12207597

Group type: EXPERIMENTAL
Intervention: Dithranol short contact therapy
Number of subjects: 216

Group type: COMPARATOR
Intervention: UVB phototherapy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Inpatient dithranol treatment
Number of subjects: 216
Study: 10476894

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for one week with bioabsorbable membrane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polylactide bioabsorbable membrane alone
Number of subjects: 24
Study: 9412747

Group type: EXPERIMENTAL
Intervention: 0.5% P4S3 in pet.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% P4S3 in pet.
Number of subjects: 0
Study: 8229546

Group type: EXPERIMENTAL
Intervention: Timed-release 5-ASA (50 mg/kg/day, maximum 3 g/day) for 8 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 14
Study: 2431074

Group type: EXPERIMENTAL
Intervention: vidarabine monophosphate (ara-AMP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: acyclovir (ACV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 27
Study: 30464435

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26062916

Group type: EXPERIMENTAL
Intervention: Caffeine Ingestion (6 mg/kg BW)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caffeine Rinse (1.14%)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caffeine Ingestion + Rinse
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25274568

Group type: EXPERIMENTAL
Intervention: Bitter drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 0
Study: 23588439

Group type: EXPERIMENTAL
Intervention: Strength training (S; n = 19)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Endurance training (E; n = 25)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of endurance and strength training (SE; n = 22)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physical activity group (PA; n = 18)
Number of subjects: 66
Study: 20378504

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with FOLFOX6 (leucovorin 5‐fluorouracil/oxaliplatin); cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly and FOLFOX6 regimen every 2 weeks consisting of oxaliplatin 85 mg/m2, LV 400 mg/m2, and 5‐FU bolus 400 mg/m2 followed by 5‐FU continuous infusion 2400 mg/m2 over 46 hours.
Number of subjects: 82
Study: 18564988

Group type: EXPERIMENTAL
Intervention: Torque Teno Virus (TTV) infection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Patients on calcineurin inhibitors (CNI) and azathioprine or mycophenolate mofetil
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Liver cirrhosis patients
Number of subjects: 25
Study: 17037284

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (ACE inhibitors, beta-antagonists, diuretics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose aspirin (300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose aspirin (not specified)
Number of subjects: 0
Study: 12428175

Group type: EXPERIMENTAL
Intervention: Rapeseed oil-based cheese
Number of subjects: 31

Group type: COMPARATOR
Intervention: Milk-fat-based control cheese
Number of subjects: 31
Study: 10349919

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA) with bupivacaine 0.125% and fentanyl 5 microg/ml
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lumbar Epidural Analgesia (LEA) with morphine 0.2 microg/ml
Number of subjects: 22
Study: 7575771

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily, increased to target levels of LDL cholesterol between 2.3 mmol/l (90 mg/dl) and 3.6 mmol/l (140 mg/dl)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Simvastatin (various dosages: 40 mg, 20 mg, 10 mg, 5 mg)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 168
Study: 7870911

Group type: EXPERIMENTAL
Intervention: Cocaine (2 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3710668

Group type: EXPERIMENTAL
Intervention: Bicycle exercise tests
Number of subjects: 18
Study: 30278936

Group type: EXPERIMENTAL
Intervention: Surgical Apgar Score (SAS) risk categories (low: SAS 7-10, intermediate: SAS 5-6, high: SAS 0-4)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Surgical Apgar Score (SAS)
Number of subjects: 405
Study: 25348683

Group type: EXPERIMENTAL
Intervention: Artificial pancreas (AP) system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 16
Study: 24474396

Group type: EXPERIMENTAL
Intervention: Adoptive cell therapy with TIL and high-dose aldesleukin after 12 Gy TBI
Number of subjects: 0
Study: 21917306

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 316
Study: 20538634

Group type: EXPERIMENTAL
Intervention: Intravitreous bevacizumab (1.25 mg, three loading injections at six week intervals)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Intravitreous bevacizumab
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard care (pegaptanib sodium, verteporfin, sham)
Number of subjects: 131
Study: 18575048

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (ropivacaine 0.2% 10 ml, followed by an infusion of 5 ml/h for 96 hours)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Intravenous opioid analgesia (morphine hydrochloride 0.1 mg/kg IV every 4-6 hours as needed, with or without ketorolac trometamol up to 90 mg/day IV)
Number of subjects: 188
Study: 16020979

Group type: EXPERIMENTAL
Intervention: gemcitabine plus oral etoposide (GE group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: gemcitabine plus cisplatin (GP group)
Number of subjects: 89
Study: 12464648

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy screening
Number of subjects: 56532
Study: 10493324

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 1800 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amitriptyline (25 to 75 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gabapentin and Amitriptyline
Number of subjects: 21
Study: 8952651

Group type: EXPERIMENTAL
Intervention: Screening with faecal occult blood testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1775082

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol (TTS 50) at 50 micrograms/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 50
Study: 7282752

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (before administration of hydralazine or isosorbide dinitrate)
Number of subjects: 15
Study: 31306527

Group type: EXPERIMENTAL
Intervention: Trifarotene 50 μg/g cream
Number of subjects: 453
Study: 30341767

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 75
Study: 28077588

Group type: EXPERIMENTAL
Intervention: SeV-Gag primed followed by Ad35-GRIN boost (SLA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SeV-Gag primed followed by Ad35-GRIN boost (SHA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ad35-GRIN alone (Control)
Number of subjects: 65

Group type: COMPARATOR
Intervention: SeV-Gag alone (Control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ad35-GRIN primed followed by SeV-Gag boost (ASH)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SeV-Gag primed followed by SeV-Gag boost (SHSH)
Number of subjects: 65
Study: 25891302

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise (EX group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Printed education material regarding physical activity (PA group)
Number of subjects: 100
Study: 24241092

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (600 mg) and vitamin E (400 IU)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) with and without ALA
Number of subjects: 85

Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 85
Study: 21798991

Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) among women without previous vaginal deliveries
Number of subjects: 227

Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) among women without previous vaginal deliveries
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) when gestation exceeded 16 weeks
Number of subjects: 227

Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) when gestation exceeded 16 weeks
Number of subjects: 227
Study: 19846849

Group type: EXPERIMENTAL
Intervention: Intensified blood-pressure control (target 24-hour mean arterial pressure below the 50th percentile)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Intensified blood-pressure control
Number of subjects: 385
Study: 17584910

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimen consisting of vincristine (2 mg/m2), doxorubicin (90 mg/m2), cyclophosphamide (2,200 mg/m2) and ifosfamide (2,800 mg/m2/day x 5 days), etoposide (100 mg/m2/day x 5 days) over 51 weeks
Number of subjects: 60
Study: 15502293

Group type: EXPERIMENTAL
Intervention: Individualized training through a multi‐faceted injury prevention program (4 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (Group B) received intervention during weeks 18-21
Number of subjects: 16
Study: 11162418

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol 800 microg
Number of subjects: 16
Study: 9580247

Group type: EXPERIMENTAL
Intervention: Insulin Lispro (IL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular insulin (RI)
Number of subjects: 10
Study: 8155220

Group type: EXPERIMENTAL
Intervention: Daily 10-minute perineal massage
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Attending physician awareness of group assignment
Number of subjects: 46
Study: 2837078

Group type: EXPERIMENTAL
Intervention: 1 g elemental phosphorus as neutral sodium‐potassium phosphate in grape juice or in water
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.7 g NaCl in juice
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.5 g phosphorus in juice
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1-1.5 g phosphorus
Number of subjects: 18
Study: 30535271

Group type: EXPERIMENTAL
Intervention: Spondee singlets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Spondee triplets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Connected discourse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Follow-up experiment with older adults (not specified as control)
Number of subjects: 36
Study: 29722944

Group type: EXPERIMENTAL
Intervention: Oral tadalafil once daily
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral tadalafil on demand
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral tadalafil once-daily + on-demand
Number of subjects: 76
Study: 25582563

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 26

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 26
Study: 23391033

Group type: EXPERIMENTAL
Intervention: Inlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Onlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inlay preparations, zirconia ceramic (ICE Zirkon)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Onlay preparations, zirconia ceramic (ICE Zirkon)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intact teeth (control)
Number of subjects: 50
Study: 20530505

Group type: EXPERIMENTAL
Intervention: Non-infarct-related artery (IRA) PCI
Number of subjects: 2201

Group type: COMPARATOR
Intervention: IRA-only PCI
Number of subjects: 2201
Study: 18728526

Group type: COMPARATOR
Intervention: 1 g fructose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 15 g fructose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 45 g fructose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fructose restriction after positive test results
Number of subjects: 32
Study: 16608040

Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg per day (group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No antifibrotic agent (group B)
Number of subjects: 38
Study: 14594883

Group type: COMPARATOR
Intervention: Control group (without heart disease)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Non-HF patients
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: GP-HF patients
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Hospital-HF patients
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Hospital-HF (multivariate predictors)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: GP-HF (multivariate predictors)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Non-HF heart disease (multivariate predictors)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction (multivariate predictors)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: No response to questionnaire (multivariate predictors)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Higher age (for every 10 years) (multivariate predictors)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Male sex (multivariate predictors)
Number of subjects: 2157
Study: 10697443

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 54
Study: 8638516

Group type: EXPERIMENTAL
Intervention: Restrained knuckle height isoinertial strength (RK)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Step-wise multiple regression analysis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Validation on a different sample (N = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Muscle activation levels
Number of subjects: 22
Study: 1426099

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (HDAra-C) as a single agent for induction therapy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (HDAra-C) plus mAMSA
Number of subjects: 143
Study: 4001887

Group type: EXPERIMENTAL
Intervention: Lewis blood group testing in patients with primary Sjögren's syndrome
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (general population)
Number of subjects: 75
Study: 30452713

Group type: EXPERIMENTAL
Intervention: Albendazole treatment (3-monthly for 1 year)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (uninfected subjects)
Number of subjects: 300
Study: 29215519

Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter plus oxytocin infusion
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oxytocin infusion alone
Number of subjects: 201
Study: 26868849

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salicylic acid/betamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcipotriol/betamethasone
Number of subjects: 30
Study: 25238439

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with levobupivacaine (150 mg), ketorolac (30 mg), and adrenaline (0.5 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (saline infiltration)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 56
Study: 21868390

Group type: EXPERIMENTAL
Intervention: Younger group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 0
Study: 20012089

Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP) using CupPrint(TM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Immunohistochemistry (IHC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Gene expression profiling (GEP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both IHC and GEP
Number of subjects: 43
Study: 16824044

Group type: EXPERIMENTAL
Intervention: Mothers employed in agriculture
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Mothers with probable exposure to pesticides
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Fathers with indirect contact with agricultural products (transport and retail)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Mothers aged below 25
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Presence of genital disease in the father
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Presence of genital disease in the mother
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Low birth weight of the infant
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Mothers consuming alcohol during pregnancy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Couples who conceived while using condoms
Number of subjects: 293
Study: 15836710

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily with cisapride 20 mg twice a day
Number of subjects: 94
Study: 12601321

Group type: EXPERIMENTAL
Intervention: 6 weeks of vestibular rehabilitation (VR)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 6 weeks of strengthening exercise (Control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups had vestibular rehabilitation for 12 weeks
Number of subjects: 124
Study: 10480285

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week for 6 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no rHuEpo)
Number of subjects: 25
Study: 8728306

Group type: EXPERIMENTAL
Intervention: Losartan potassium
Number of subjects: 75

Group type: COMPARATOR
Intervention: Enalapril maleate
Number of subjects: 75
Study: 1919425

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (108 +/- 6 micrograms kg-1 min-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 8
Study: 6356950

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with complete ulcer excision
Number of subjects: 30

Group type: COMPARATOR
Intervention: Partial gastrectomy with gastroduodenostomy
Number of subjects: 30
Study: 30341746

Group type: EXPERIMENTAL
Intervention: Knowledge of healthcare waste management
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Practice of healthcare waste management
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Age group 35-44 years, nurses, midwives, medical laboratory personnel
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Educational status
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Overall knowledge and practice
Number of subjects: 400